ASTRAZENECA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,642 SEK | +6.35% |
|
+9.65% | +21.28% |
| 08:44am | Miner Anglo American eyes rival BHP takeover | AN |
| 08:37am | AstraZeneca Earnings, Sales Rise, Beat Forecasts | DJ |
| Sales 2024 * | 50.81B 552B | Sales 2025 * | 54.48B 592B | Capitalization | 219B 2,377B |
|---|---|---|---|---|---|
| Net income 2024 * | 8.71B 94.6B | Net income 2025 * | 10.26B 111B | EV / Sales 2024 * | 4.7 x |
| Net Debt 2024 * | 19.83B 215B | Net Debt 2025 * | 12.92B 140B | EV / Sales 2025 * | 4.25 x |
| P/E ratio 2024 * |
25.7
x | P/E ratio 2025 * |
21.7
x | Employees | 89,900 |
| Yield 2024 * |
2.19% | Yield 2025 * |
2.3% | Free-Float | 96.5% |
More Fundamentals
* Assessed data
More news
Latest transcript on AstraZeneca PLC
More recommendations
More press releases
More news
| 1 day | +1.41% | ||
| 1 week | +2.69% | ||
| Current month | +6.27% | ||
| 1 month | +9.90% | ||
| 3 months | +11.04% | ||
| 6 months | +8.16% | ||
| Current year | +14.04% |
1 week
1 481.00
1 552.50
1 month
1 387.501 552.50
Current year
1 261.001 552.50
1 year
1 261.001 616.00
3 years
863.601 616.00
5 years
700.001 616.00
10 years
447.501 616.00
| Managers | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 63 | 12-09-30 |
Aradhana Sarin
DFI | Director of Finance/CFO | 50 | 21-07-31 |
Cindy Hoots
CTO | Chief Tech/Sci/R&D Officer | 56 | 19-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sherilyn McCoy
BRD | Director/Board Member | 65 | 17-09-30 |
Ahmed Hamdy
PRN | Corporate Officer/Principal | 59 | 13-01-31 |
Philip Broadley
BRD | Director/Board Member | 63 | 17-04-26 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 1,642 | +6.35% | 917 143 |
| 24-04-24 | 1,544 | +1.41% | 341,079 |
| 24-04-23 | 1,522 | -0.49% | 243,301 |
| 24-04-22 | 1,530 | +2.34% | 306,741 |
| 24-04-19 | 1,494 | -0.17% | 230,033 |
Delayed Quote Nasdaq Stockholm, April 24, 2024 at 11:29 am EDT
More quotes
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
02:00am
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
141.1
USD
Average target price
161.4
USD
Spread / Average Target
+14.36%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +25.61% | 660B | |
| +25.87% | 562B | |
| -5.24% | 358B | |
| +16.49% | 322B | |
| +8.28% | 297B | |
| -9.12% | 196B | |
| +5.01% | 199B | |
| -8.75% | 149B | |
| -5.21% | 146B |
- Stock Market
- Equities
- AZN Stock
- AZN Stock
